TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Quoin Pharmaceuticals ( (QNRX) ) has shared an update.
On November 14, 2025, Quoin Pharmaceuticals‘ Board of Directors approved new award agreements for stock options under the company’s 2025 Equity Incentive Plan. These agreements outline the terms for granting equity awards to directors and executive officers, including various payment methods for exercising options and conditions for awards upon termination of employment. This move aims to enhance the company’s ability to attract and retain top talent, potentially impacting its competitive position in the pharmaceutical industry.
The most recent analyst rating on (QNRX) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Quoin Pharmaceuticals stock, see the QNRX Stock Forecast page.
Spark’s Take on QNRX Stock
According to Spark, TipRanks’ AI Analyst, QNRX is a Underperform.
Quoin Pharmaceuticals is in a challenging financial position with no revenue generation and high reliance on external financing. The technical analysis indicates a bearish trend, though some technical indicators suggest the stock may be oversold. Valuation metrics reflect the company’s lack of profitability. The combination of these factors results in a low stock score, highlighting significant risks to investors.
To see Spark’s full report on QNRX stock, click here.
More about Quoin Pharmaceuticals
Quoin Pharmaceuticals Ltd. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative therapeutic products. The company is committed to advancing treatments that address unmet medical needs, particularly in niche markets.
Average Trading Volume: 622,167
Technical Sentiment Signal: Sell
Current Market Cap: $8.84M
Learn more about QNRX stock on TipRanks’ Stock Analysis page.